Bayer's $7.25B Roundup Deal Lands in Judge Boyer's Courtroom Monday — and the Verdict Reshapes Every Ag-Chem and Product-Liability Balance Sheet

Judge Timothy Boyer of the 22nd Judicial Circuit in St. Louis will preside over the rescheduled fairness hearing beginning Monday, Sept. 14, 2026. The venue is deliberate: Bayer/Monsanto filed the proposed nationwide class settlement in Missouri state court precisely because the circuit has handled the bulk of Roundup bellwether trials since 2018 and because the judge sits closest to the company’s U.S. crop-science headquarters in Creve Coeur. The federal track tried to derail that strategy — ten non-Hodgkin lymphoma plaintiffs attempted to remove the deal to federal court in May2026 — but Judge Henry Edward Autrey remanded it back to state court on June 17, ruling that only defendants may invoke federal jurisdiction over a class action.

Boyer is not expected to issue an immediate ruling. He will weigh objections from objector-attorneys arguing that the tiered payout structure under-compensates claimants with aggressive NHL and rewards a small group of plaintiff firms with fee awards that scale to total settlement size. He will also hear supporting counsel frame the deal as the only realistic alternative to years of individual trials. The deal covers claims by people diagnosed with non-Hodgkin lymphoma before the settlement's effective date or within a 16-year tail that runs after final approval and the exhaustion of appellate rights.

Bayer's biggest litigation win of 2026 already happened. On June 25, the U.S. Supreme Court ruled 7–2 in Monsanto Co. v. Durnell that FIFRA expressly preempts state-law failure-to-warn claims against pesticide makers when the EPA has made a definitive safety finding. The decision overturned a $1.25 million verdict for a Missouri man and gives Bayer a federal shield against the most plaintiff-friendly theory in the docket. The state-court class settlement exists because the Supreme Court didn't kill all of the theories — claims rooted in design defect, public nuisance, and consumer fraud still survive, and they still number in the tens of thousands.

Bayer raised provisions and litigation liabilities from €7.8 billion ($9.24B) at year-end 2025 to €11.8 billion at the time of the February 2026 settlement announcement, and guided for roughly €5 billion in litigation-related cash payouts during 2026 alone. The proposed structure — declining capped annual installments over up to 21 years — back-loads the cost. The class covers any Roundup-exposed U.S. resident diagnosed with NHL before settlement plus a 16-year forward window, so the longest-dated exposure tail runs into the 2040s. That tail is what the Missouri court must approve, because the company reserves the right to terminate the class settlement if opt-outs exceed a defined threshold.

Apollo Global Management's €3 billion equity injection in July 2026, for a minority stake in Bayer's long-acting reversible contraceptives (LARC) entity, is the cash-flow pivot. It refinanced the balance sheet ahead of the settlement, allowing Bayer to revise its net-debt guidance down to €29–30 billion for year-end 2026 even as2026 free cash flow ran negative €371 million in Q2 alone. Ruveon LLC, a separate Bayer subsidiary created July 1, 2026 to house the U.S. glyphosate business, adds a second structural lever: it isolates the U.S. Roundup franchise from the parent, a step lawyers and analysts have read as a litigation firewall that could, over time, support an outright divestiture of the herbicide business.

Roundup is the load-bearing asset in the U.S. glyphosate market — Bayer/Monsanto supplies roughly 40% of global volume, and the brand generated about $2.4 billion in 2024 revenue. A plaintiff-friendly ruling in St. Louis would re-open individual trials and risk multipliers comparable to the 2024 Philadelphia $2.25 billion verdict and the Georgia $2.1 billion punitive award; a defense ruling freezes the litigation discount that has weighed on every ag-chem multiple since 2018. The downstream consequence is the relative re-rating of independent U.S. peers.

Corteva is the cleanest read-through. The company pulled Enlist Duo — its own glyphosate-plus-2,4-D herbicide — in February 2026 after a decade of litigation by the Center for Food Safety, and its Q2 2026 crop-protection sales fell to $1.85 billion as channel inventory normalized. A Missouri defense verdict would let Corteva's seeds-and-traits multiple re-rate toward the higher end of its historical band; a plaintiff verdict would tighten the litigation discount that already hangs over the entire U.S. selective-herbicide market. FMC's read-through is weaker but still relevant: a plaintiff win would re-price category exposure and could push FMC's $1.51 billion market cap below its already depressed book value.

The Roundup deal is now the third multi-decade U.S. product-liability class program of the past18 months, and the other two are still in flight. Johnson & Johnson announced a proposed $5.5 billion settlement in July 2026 to resolve roughly 76,000 ovarian-cancer claims over its talc-based products, after reversing about $7 billion of prior reserves in March 2025.3M's $10.3 billion PFAS public-water settlement, approved in2024 and paid over 13 years, is already in cash-out mode. Together with Bayer's deal, the three programs redefine how S&P 500 product-liability reserves get modeled: capped, declining, multi-decade amortizations with explicit future-claim components.

Three structural scenarios branch from Monday's ruling. In a defense scenario, the $7.25 billion cap becomes a known liability, Ruveon is parked as a strategic option, and Bayer's Crop Science segment — which posted €4.91 billion in Q2 sales (+3.5%) and a 30% EBITDA-before-special-items jump on glyphosate momentum — re-rates toward its 2018 peak multiple. The class also locks in a federal precedent that pushes plaintiff bars toward structured class settlements over individual bellwethers, the same template Johnson & Johnson and 3M are already following.

In a plaintiff scenario, the 65,000-claim pool returns to active litigation, and Bayer's German parent faces renewed pressure to either sell the Crop Science division outright or re-spin it via Ruveon. The market reaction is mechanical: every $1 billion of incremental contingent liability reduces the present value of the Crop Science segment by roughly €0.9 billion at an 8% discount rate. The split between parent and Ruveon also becomes a test case for whether litigation can be structurally walled off in a U.S. ag-chem context.

In a mixed scenario — partial approval, modified tier structure, or a continuance — the deal's16-year forward window becomes the pivot. Courts can shorten the future-claim tail without rejecting the deal, and that single lever is what determines whether Bayer's exposure is a 21-year tail or a 10-year tail. Watch the hearing transcript for any signaled modification; a tightened tail materially lowers present-value cost even if total dollars stay the same.